Secondary cytoreduction is a treatment option for selected patients with platinum-sensitive relapsed ovarian cancer despite controversial long-term outcomes. In the last 5 years, three randomized trials comparing surgery plus chemotherapy versus chemotherapy alone have been published—namely,
No takes yet. Share an insight, caveat, or question.
Gouveia et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: